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The D-dimer and B-type natriuretic peptide (BNP) levels in relation to CHADS2 and CHA2DS2–VASc
scores in 59 patients with atrial ﬁbrillation who were not receiving anticoagulant therapy were
analyzed. Among 19 patients with CHADS2 scores of 0–1, 3 of the 7 patients with elevated BNP levels
also had elevated D-dimer levels. Among 8 patients with CHA2DS2–VASc scores of 1, 2 of the 3 patients
with elevated BNP levels also had elevated D-dimer levels. Therefore, D-dimer levels can be elevated in
low-risk patients when BNP levels are high, and anticoagulation therapy should be considered for these
patients.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Congestive heart failure (CHF) is known as an established risk
factor for stroke in patients with atrial ﬁbrillation (AF) [1].
However, diagnosing CHF is occasionally difﬁcult because of the
symptoms that are similar to those of AF, such as dyspnea and
palpitations. The adjusted annual stroke rates in AF patients with
a CHADS2 (CHF, hypertension, ageZ75 years, diabetes, stroke
[doubled]) scores of 0 and 1 were reported to be 1.9% and 2.8%,
respectively, but these patients were not necessarily considered
to have a low-risk for stroke [2]. It can be speculated that latent
CHF might have been undiagnosed in patients with low CHADS2
scores. B-type natriuretic peptide (BNP) can be used as a marker
for the differential diagnosis of CHF and could serve as a risk
marker in addition to clinical assessment. D-dimer can be used as
a coagulation marker in patients with AF [3–5]. We reported that
the D-dimer levels predicted subsequent thromboembolic events
in AF patients and that BNP levels could be a useful marker for
predicting thromboembolic events [6,7]. Recently, the European
Society of Cardiology guideline [8] recommended that CHA2DS2–
VASc (CHF/left ventricular dysfunction, hypertension, ageZ75
years [doubled], diabetes, stroke [doubled], vascular disease, age
of 65–74 years, and sex category [female]) score [9] instead of
CHADS2 score should be used for risk stratiﬁcation. In the presentrt Rhythm Society. Published by E
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naga).study, we analyzed D-dimer levels in relation to CHADS2 and
CHA2DS2–VASc scores to evaluate the usefulness of measuring
BNP levels in AF patients before initiating anticoagulant therapy.2. Methods
In our present study, we performed a post hoc analysis of the
results of our previous study [10]. Brieﬂy, 59 patients for whom
BNP and D-dimer levels were determined on the same day and
who had not started warfarin therapy were included.
The study protocol was approved by the institutional ethics
committee, and informed written consent was obtained from all
of the patients included in this study.
Data were presented as mean7SD, median (interquartile
range), or percentage values, as appropriate. Comparisons between
the 2 groups of data were made with the unpaired Student t test or
Mann–Whitney test, as appropriate. Event frequencies were com-
pared using the chi-square test. A po0.05 was considered statis-
tically signiﬁcant. The statistical software package JMP (version 9,
SAS Institute, Cary, NC, USA) was used for the analyses. The cutoff
values for D-dimer and BNP levels were set at 0.5 mg/mL and
100 pg/mL, respectively, according to previous reports [6,10].3. Results
The clinical characteristics of the patients are presented in
Table 1. The mean CHADS2 score was 2.071.1. There were 6, 13,lsevier B.V. All rights reserved.
Table 1
Clinical characteristics of the patients.
Total CHADS2 score 0–1 (n¼19) CHADS2 scoreZ2 (n¼40)
BNPo100 pg/mL BNPZ100 pg/mL p value BNPo100 pg/mL BNPZ100 pg/mL p value
n 59 12 7 7 33
Age (y/0) 76710 70711 6877 0.70 6979 8177 o0.01
AgeZ75 y/o n (%) 32 (54) 4 (33) 0 (0) 0.086 2 (29) 26 (79) o0.01
Female n (%) 28 (48) 5 (42) 1 (14) 0.22 4 (57) 18 (55) 0.90
Chronic AF n (%) 21 (36) 2 (17) 4 (57) 0.067 2 (29) 13 (39) 0.59
CHF n (%) 25 (42) 0 (0) 0 (0) 1 (14) 24 (73) o0.01
Hypertension n (%) 34 (58) 4 (33) 3 (43) 0.68 6 (86) 21 (64) 0.30
Diabetes mellitus n (%) 15 (25) 0 (0) 2 (28) 0.050 4 (57) 9 (28) 0.13
History of stroke n (%) 6 (10) 0 (0) 0 (0) 1 (14) 5 (15) 0.95
BNP levels (pg/mL) 85 (56–351) 36 (15–60) 182 (133–220) o0.01 31 (24–56) 255 (209–432) o0.01
BNP Z100 pg/mL n (%) 40 (68) 0 (0) 7 (100) o0.01 0 (0) 33 (100) o0.01
BNP Z200 pg/mL n (%) 29 (48) 0 (0) 3 (43) 0.014 0 (0) 26 (79) o0.01
D-dimer levels (mg/mL) 0.91 (0.36–2.1) 0.30 (0.0–0.42) 0.44 (0.35–0.70) 0.10 0.47 (0.0–0.91) 1.52 (0.91–4.3) o0.01
D-dimer Z0.5 mg/mL n (%) 37 (63) 1 (8.3) 3 (43) 0.075 3 (43) 30 (91) o0.01
Structural heart disease n (%) 27 (46) 4 (33) 0 (0) 0.086 3 (43) 20 (61) 0.39
Hypertensive heart disease n (%) 19 (32) 3 (25) 0 (0) 0.15 3 (43) 13 (39) 0.87
Valvular heart disease n (%) 7 (12) 0 (0) 0 (0) 0 (0) 7 (21) 0.18
Coronary artery disease n (%) 6 (10) 0 (0) 0 (0) 1 (14) 5 (15) 0.95
Medications
Aspirin (100 mg/day) n (%) 13 (22) 1 (8.3) 0 (0) 0.62 3 (43) 9 (27) 0.41
ACEI/ARB n (%) 39 (66) 5 (42) 5 (71) 0.21 4 (57) 25 (76) 0.32
b blockers n (%) 14 (24) 4 (33) 0 (0) 0.086 2 (29) 8 (24) 0.81
Diuretics n (%) 21 (36) 1 (8.3) 0 (0) 0.62 1 (14) 19 (58) 0.038
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin type II receptor blocker; BNP: B-type natriuretic peptide; CHF: congestive heart failure; p value:
BNPo100 pg/mL vs. BNPZ100 pg/mL in the same category.
Fig. 1. Percentage of the patients with high D-dimer levels (Z0.5 mg/mL) in
relation to the CHADS2 scores and BNP levels. The numbers shown in the bar
denote the number of patients in each category. Fig. 2. Percentage of patients with high D-dimer levels in relation to the CHA2DS2–
VASc scores and BNP levels.
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The D-dimer levels were signiﬁcantly higher in the patients with
CHADS2 scores Z2 than in those with CHADS2 scores of 0–1
(median D-dimer level, 1.16 mg/mL [0.72–3.23 mg/mL] vs. 0.36 mg/mL
[0.0–0.44 mg/mL], po0.01).
In the patients with clinically diagnosed CHF (NYHA class ZII
symptoms and/or congestive signs requiring loop diuretics), the
median BNP level was 371 pg/mL (236–450 pg/mL), and BNP levels
were elevated (Z100 pg/mL) in 24 (96%) of the 25 patients. In
the 34 patients without CHF, the median BNP level was 77 pg/mL
(26–175 pg/mL), and BNP levels were elevated in 16 patients (47%).
Fig. 1 shows the percentage of patients with high D-dimer
levels (Z0.5 mg/mL) in relation to the CHADS2 scores and BNP
levels. The D-dimer levels were elevated in 33 (83%) of the 40
patients with CHADS2 scores Z2. None of the patients with
CHADS2 scores of 1 had CHF. Among the 19 patients with CHADS2scores of 0 or 1, the D-dimer levels were elevated in 3 (43%) of the
7 patients with elevated BNP levels and in only 1 (8.3%) of the 12
patients whose BNP levels were not elevated (p¼0.075). Further-
more, in 6 patients with CHADS2 scores of 0, the D-dimer levels
were elevated in 1 of the 2 patients with elevated BNP levels but
not in the remaining 4 patients whose BNP levels were not
elevated.
Fig. 2 shows the percentage of patients with high D-dimer
levels in relation to the CHA2DS2–VASc scores and BNP levels.
None of the patients had a CHA2DS2–VASc score of 0. The BNP
levels were elevated in 3 (38%) of the 8 patients with CHA2DS2–
VASc scores of 1, and the D-dimer levels were elevated in 2 of
these 3 patients. Among the patients with CHA2DS2–VASc scores
of 1, none of the 5 patients whose BNP levels were not elevated
had elevated D-dimer levels.
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BNP levels have been shown to be elevated in patients with AF
[11,12], even in those who have preserved left ventricular systolic
function. As shown in Figs. 1 and 2, the D-dimer levels were
elevated in some patients with low CHADS2 or CHA2DS2–VASc
scores who did not have CHF but had elevated BNP levels. Using
the RE-LY database, Hijazi et al. [13] recently reported that the
annual rate of composite thromboembolic events was even higher
in AF patients with high (top-quartile) NT-proBNP levels and
CHADS2 scores of 0 or 1 than in patients with CHADS2 scores Z3
and low (lowest-quartile) NT-proBNP levels. Although this study
used D-dimer levels as a surrogate marker for thromboembo-
lisms, our results were consistent with those of Hijazi et al. [13].
It can be speculated that latent CHF with a possible hypercoagul-
able state was undiagnosed in patients with few clinical risk
factors, although some other factors that might cause a hyper-
coagulable state other than CHF might coexist.5. Limitations
First, although high D-dimer levelsZ0.5 mg/mL could predict
thromboembolic events in patients with AF during anticoagula-
tion therapy [6], it is not known whether these levels could be
applied to patients who are not undergoing anticoagulant ther-
apy. Second, we performed a post hoc analysis with a small
number of patients; thus, there might have been selection biases.
Therefore, drawing deﬁnite conclusions was not possible.6. Conclusions
Therefore, D-dimer levels can be elevated in AF patients with
few clinical risk factors when BNP levels are high, and antic-
oagulation treatment should be considered for these patients.Conﬂict of interest
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